Background

At the 14th world congress of the International Hepato-Pancreato-Biliary Association (IHPBA) 2020, Prof. Efanov from Moscow Clinical Research Center presented data from a single-center randomized prospective trial (poster presentation PG04-04). The title of the presentation was *A Single-Center Prospective Randomized Study for Comparison of Water Jet Dissector and Ultrasonic Aspirator in the Division of the Liver Parenchyma during Laparoscopic Resection*.

The adoption of laparoscopic liver resection in clinical daily practice is ongoing and the quality is increasing with the learning curve.

For parenchyma transection, different selective and non-selective techniques have been described. Ultrasonic aspirator and high-pressure waterjet belong to the selective modalities that are frequently used. Comparative data on both these techniques is lacking.

Method

The working group, led by Prof. Efanov, conducted a two-arm prospective randomized single-center trial (clinicaltrials.gov: NCT03208192). 68 patients were included. All patients underwent a laparoscopic liver resection for benign or malignant conditions. The parenchyma transection was conducted either using ultrasonic aspiration or high-pressure waterjet.

Primary endpoint was the intraoperative blood loss. It was measured as absolute volume and calculated in relation to the liver resection surface.

Challenges and goals

Efanov et al. aimed to evaluate safety and feasibility of selective parenchyma transection in laparoscopic liver resection in this investigator-initiated trial.
Implications and recommendations

High-pressure waterjet and ultrasonic aspirator have similar efficacy and safety in parenchyma transection in laparoscopic liver resection. In this study, no significant difference in parenchyma transection time was found. Another single-center, retrospective study was able to identify a quicker dissection of the waterjet compared with the ultrasonic aspirator in open parenchyma transection of living organ donors. The authors concluded that prospectively randomized data from multiple centers would be needed to objectively confirm this observation. In their publication, Hamaoka et al. stress the short learning curve when using the ERBEJET® 2.

The relatively small groups and the single-center involvement of the study of Efanov et al. limit the transferability to other patient populations.

Products

ERBEJET® 2 was used with an effect setting of 35 – 40. Further, the straight laparoscopic applicator with integrated suction (No. 20150-038) was used. The ESM 2 was operated with -100 mbar suction.

Results and key findings

There were no differences in patient-related and surgical characteristics.

The intraoperative blood loss did not differ significantly between the groups. Transection duration, Pringle maneuver time, complication rate and hospital stay also were not significantly different. A significantly higher total bilirubin level on the second post-operative day was observed in the ultrasonic aspirator group.

There was a significant difference in the costs per operation in favor of high-pressure waterjet transection.

<table>
<thead>
<tr>
<th></th>
<th>High-pressure waterjet</th>
<th>Ultrasonic aspirator</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blood loss in volume per resection area (ml/cm²)</td>
<td>3.8 (0.2–10.6)</td>
<td>3.4 (0.8–10.0)</td>
<td>0.555</td>
</tr>
<tr>
<td>Absolute blood loss in ml</td>
<td>186 (10–400)</td>
<td>206 (50–600)</td>
<td>0.897</td>
</tr>
<tr>
<td>Transection duration in minutes per resection area (min/cm²)</td>
<td>2.3 (0.5–6.4)</td>
<td>2.6 (0.6–7.2)</td>
<td>0.525</td>
</tr>
<tr>
<td>Absolute transection duration in minutes</td>
<td>107 (19–305)</td>
<td>99 (20–300)</td>
<td>0.714</td>
</tr>
<tr>
<td>Total pringle maneuver time in minutes</td>
<td>12 (0–59)</td>
<td>11 (0–48)</td>
<td>0.908</td>
</tr>
<tr>
<td>Hospital stay in days</td>
<td>7.9 (5.0–19.0)</td>
<td>8.3 (4.0–15.0)</td>
<td>0.240</td>
</tr>
<tr>
<td>Costs per surgery in €</td>
<td>1003 (982–1057)</td>
<td>2529 (2505–2585)</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

References

Important information
We have prepared this document with care. Nonetheless, we cannot completely rule out errors in this document.

The information, recommendations and other data ("Information") contained in this document reflect our state of knowledge and the state of science and technology at the time of preparing the document. The information is of a general nature, non-binding and serves solely for general information purposes and does not represent instructions for use or notes on application.

The information and recommendations contained in this document do not constitute any legal obligations on Erbe Elektromedizin GmbH or their associated companies ("Erbe") or any other claims against Erbe. The information does not represent a guarantee or other quality statement; these require an express contractual arrangement with Erbe in individual cases.

Erbe shall not be liable for any type of damage resulting from following information given in this document, regardless of the legal reason for liability. Every user of an Erbe product is responsible for checking the respective Erbe product for its properties as well as the suitability for the intended type of application or intended purpose in advance. The suitable type of application of the respective Erbe product is given by the user manual and the notes on use for the corresponding Erbe product. The user is obliged to check whether the existing user manual and the notes on use correspond with the status for the specific Erbe product. The devices may only be used according to the user manual and the notes on use.

The information on setting values, application sites, duration of application and the use of the respective Erbe product is based on the clinical experience of physicians independent from Erbe. They represent guidelines which need to be checked by the user for their suitability for the actual planned application. Depending on the circumstances of an actual application case, it may be necessary to deviate from the information provided. The user is responsible for checking this in each case when using an Erbe product. We wish to point out that science and technology is constantly subject to new developments arising from research and clinical experience. For this reason, it may be necessary for the user to deviate from the information provided in this document.

This document contains information about Erbe products which may possibly not be approved in a specific country. The user of the respective Erbe product is obliged to inform him/herself as to whether the Erbe product he/she is using is legally approved in his/her country and/or if legal requirements or restrictions for use possibly exist and to what extent.

This document is not intended for users in the USA.